CAPP3
CaPP3
CaPP3- A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological mismatch repair gene defect, Lynch Syndrome. Project 3 in the Cancer Prevention Programme
- Study stage: Follow-up
- Sponsor: Newcastle upon Tyne Hospitals NHS Foundation Trust
- Funder: Cancer Research UK, Bayer Pharma AG
- Therapeutic area: Cancer and Neoplasm
- Type of study: CTIMP
Aim: To find the best dose of aspirin that people with Lynch syndrome should take to prevent cancer. The CAPP2 trial showed that 600mg aspirin per day for 2 years reduced the incidence of colorectal cancer by over 50%.
Primary outcome:
The number of new primary mismatch repair deficient cancers (“Lynch syndrome cancers”) at 5 years and beyond which develop in participants who remain on prescribed treatment for a minimum of 2 years.
- Population: Adult
- Phase: III
- Design: RCT
- Setting: Secondary care
- Planned Sample Size: 1567
Website: http://www.capp3.org/